|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5J2 |
Gene summary for ATP5J2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5J2 | Gene ID | 9551 |
| Gene name | ATP synthase membrane subunit f | |
| Gene Alias | ATP5J2 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P56134 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9551 | ATP5J2 | GSM4909281 | Human | Breast | IDC | 4.47e-24 | -3.91e-01 | 0.21 |
| 9551 | ATP5J2 | GSM4909282 | Human | Breast | IDC | 2.52e-23 | -3.91e-01 | -0.0288 |
| 9551 | ATP5J2 | GSM4909285 | Human | Breast | IDC | 5.96e-23 | -3.91e-01 | 0.21 |
| 9551 | ATP5J2 | GSM4909286 | Human | Breast | IDC | 5.96e-23 | -3.91e-01 | 0.1081 |
| 9551 | ATP5J2 | GSM4909287 | Human | Breast | IDC | 4.02e-18 | -3.91e-01 | 0.2057 |
| 9551 | ATP5J2 | GSM4909288 | Human | Breast | IDC | 8.02e-04 | -3.91e-01 | 0.0988 |
| 9551 | ATP5J2 | GSM4909289 | Human | Breast | IDC | 1.80e-02 | -3.91e-01 | 0.1064 |
| 9551 | ATP5J2 | GSM4909290 | Human | Breast | IDC | 7.88e-13 | -3.91e-01 | 0.2096 |
| 9551 | ATP5J2 | GSM4909291 | Human | Breast | IDC | 2.70e-10 | -3.91e-01 | 0.1753 |
| 9551 | ATP5J2 | GSM4909293 | Human | Breast | IDC | 5.96e-23 | -3.91e-01 | 0.1581 |
| 9551 | ATP5J2 | GSM4909294 | Human | Breast | IDC | 1.06e-23 | -3.91e-01 | 0.2022 |
| 9551 | ATP5J2 | GSM4909295 | Human | Breast | IDC | 5.68e-08 | -3.91e-01 | 0.0898 |
| 9551 | ATP5J2 | GSM4909296 | Human | Breast | IDC | 4.47e-24 | -3.91e-01 | 0.1524 |
| 9551 | ATP5J2 | GSM4909297 | Human | Breast | IDC | 2.52e-23 | -3.91e-01 | 0.1517 |
| 9551 | ATP5J2 | GSM4909298 | Human | Breast | IDC | 1.06e-23 | -3.91e-01 | 0.1551 |
| 9551 | ATP5J2 | GSM4909299 | Human | Breast | IDC | 3.31e-22 | -3.91e-01 | 0.035 |
| 9551 | ATP5J2 | GSM4909300 | Human | Breast | IDC | 5.69e-07 | -3.91e-01 | 0.0334 |
| 9551 | ATP5J2 | GSM4909301 | Human | Breast | IDC | 2.52e-23 | -3.91e-01 | 0.1577 |
| 9551 | ATP5J2 | GSM4909302 | Human | Breast | IDC | 7.44e-18 | -3.91e-01 | 0.1545 |
| 9551 | ATP5J2 | GSM4909303 | Human | Breast | IDC | 1.98e-04 | -3.91e-01 | 0.0438 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0019023 | Breast | IDC | Oxidative phosphorylation | 62/867 | 134/8465 | 4.78e-27 | 2.59e-25 | 1.94e-25 | 62 |
| hsa0471424 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0019033 | Breast | IDC | Oxidative phosphorylation | 62/867 | 134/8465 | 4.78e-27 | 2.59e-25 | 1.94e-25 | 62 |
| hsa0471434 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0019043 | Breast | DCIS | Oxidative phosphorylation | 61/846 | 134/8465 | 9.84e-27 | 5.30e-25 | 3.90e-25 | 61 |
| hsa0471443 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
| hsa0019053 | Breast | DCIS | Oxidative phosphorylation | 61/846 | 134/8465 | 9.84e-27 | 5.30e-25 | 3.90e-25 | 61 |
| hsa0471453 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
| hsa0019018 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
| hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
| hsa0019019 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
| hsa04714110 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
| hsa00190 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
| hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
| hsa001901 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
| hsa047141 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP5J2 | SNV | Missense_Mutation | c.275A>C | p.Lys92Thr | p.K92T | P56134 | protein_coding | deleterious(0) | possibly_damaging(0.649) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ATP5J2 | SNV | Missense_Mutation | rs11545970 | c.128N>T | p.Ala43Val | p.A43V | P56134 | protein_coding | tolerated(0.06) | benign(0.358) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ATP5J2 | SNV | Missense_Mutation | novel | c.50A>C | p.Lys17Thr | p.K17T | P56134 | protein_coding | deleterious(0.02) | possibly_damaging(0.461) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP5J2 | SNV | Missense_Mutation | rs762526939 | c.265C>T | p.Arg89Trp | p.R89W | P56134 | protein_coding | tolerated(0.06) | benign(0.125) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP5J2 | SNV | Missense_Mutation | novel | c.17N>T | p.Glu6Val | p.E6V | P56134 | protein_coding | tolerated(0.25) | possibly_damaging(0.661) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP5J2 | SNV | Missense_Mutation | novel | c.22N>T | p.Pro8Ser | p.P8S | P56134 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-56-8622-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ATP5J2 | SNV | Missense_Mutation | rs771516671 | c.149N>A | p.Arg50Gln | p.R50Q | P56134 | protein_coding | tolerated(0.32) | benign(0.015) | TCGA-D7-6520-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | epirubicin | SD |
| ATP5J2 | SNV | Missense_Mutation | rs761746638 | c.220N>A | p.Val74Met | p.V74M | P56134 | protein_coding | tolerated(0.15) | benign(0.184) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |